DRGLIM-M1 Tablet | Glimepiride & Metformin Hydrochloride Prolonged Release Tablets IP

DRGLIM-M1 Tablet is a combination anti-diabetic medicine containing Glimepiride and Metformin Hydrochloride Prolonged Release. It is used in the management of Type 2 Diabetes Mellitus in adults when diet, exercise, or single-drug therapy does not provide adequate blood sugar control.

Glimepiride belongs to the sulfonylurea class, which helps the pancreas release more insulin, while Metformin Hydrochloride Prolonged Release improves insulin sensitivity and reduces glucose production in the liver. The prolonged-release formulation helps maintain stable blood glucose levels throughout the day and reduces stomach-related side effects.

DRGLIM-M1 Tablet helps control fasting and post-meal blood sugar levels, lowers the risk of diabetes-related complications, and supports long-term glycemic control when taken regularly under medical supervision.

⭐ Key Benefits

Controls Type 2 Diabetes Mellitus effectively

Improves insulin release and sensitivity

Reduces fasting and post-prandial blood sugar

Prolonged-release formula for better tolerance

Helps prevent long-term diabetic complications

✅ Composition

Glimepiride

Metformin Hydrochloride (Prolonged Release)

🩺 Usage

Take DRGLIM-M1 Tablet once daily with meals or as prescribed by your doctor. Swallow whole; do not crush or chew. Regular monitoring of blood glucose levels is advised.

⚠️ Precautions

Not recommended for Type 1 Diabetes

Use cautiously in kidney or liver disease

Avoid excessive alcohol consumption

May cause low blood sugar if meals are skipped

Consult doctor before use during pregnancy or breastfeeding

📦 Delivery Information

✔️ Fast delivery across India

✔️ Secure and tamper-proof packaging

🔄 Return Policy

✔️ Return accepted only if a wrong product is delivered

❌ No return if opened, used, or ordered incorrectly